DARE

DARE is a pre-commercial clinical-stage biotech, not an operating business you can value on fundamentals. The headline 'revenue $1.03M, +10,429% YoY' is an illusion: the 10-K states it 'primarily relates to the license fee recognized upon termination of our license agreement with Bayer,' with the only recurring line being non-cash XACIATO royalties already pledged away to UiE under a royalty-interest financing deal. So there is essentially no organic product revenue, yet the stock trades at 29.5x that number and the company has never posted a profit — a -$189M accumulated deficit and five straight years of losses (-$38.7M, -$30.9M, -$30.2M, -$4.05M, -$13.4M) tell the real story.

The balance sheet is thin and the runway is finite. Cash of $24.7M against a -$9.89M operating cash burn is roughly two-plus years of runway, but stockholders' equity is only $2.84M against $29.6M of liabilities (10.42x leverage), and shares outstanding jumped 64.5% in a single year. That dilution is the actual funding mechanism here, and at a $30.4M market cap every raise is heavily dilutive to existing holders. ROE of -471% and a -1,300% net margin are not ratios to analyze so much as confirmation that traditional profitability metrics don't yet apply.